Viatris (VTRS) Long-Term Debt Issuances (2019 - 2023)
Viatris' (VTRS) quarterly Long-Term Debt Issuances came in at $300000.0 in Q4 2023, up 200.0% year-on-year from $100000.0 in Q4 2022, and up 200.0% quarter-over-quarter from $100000.0 in Q4 2022.
Viatris (VTRS) Long-Term Debt Issuances (2019 - 2023) Analysis & Trends
Viatris' Long-Term Debt Issuances history runs 5 years deep, the most recent figure standing at $300000.0 for Q4 2023.
- On a quarterly basis, Long-Term Debt Issuances rose 200.0% year-over-year to $300000.0 in Q4 2023; TTM through Dec 2023 was $300000.0, a 99.98% decrease from a year earlier, with the FY2023 full-year figure at $300000.0, down 99.98% from the prior year.
- Long-Term Debt Issuances rose to $300000.0 in Q4 2023 per VTRS's latest filing, from $100000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $11.4 billion in Q2 2020 and bottomed at $100000.0 in Q1 2022.
- The 5-year median for Long-Term Debt Issuances is $795.3 million (2022), against an average of $1.5 billion.
- Across the five-year window, Long-Term Debt Issuances soared 12739.19% in 2020 and plunged 92.1% in 2021, its largest moves.
- Year by year, Long-Term Debt Issuances stood at $7.4 million in 2019, then surged by 12739.19% to $950.1 million in 2020, then declined by 14.75% to $810.0 million in 2021, then slumped by 99.99% to $100000.0 in 2022, then soared by 200.0% to $300000.0 in 2023.
- Per Business Quant, the three latest VTRS Long-Term Debt Issuances figures stand at $300000.0 (Q4 2023), $100000.0 (Q4 2022), and $1.1 billion (Q3 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 4.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 1.08 Bn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 795.30 Mn |
| Jun 30, 2022 | 795.30 Mn |
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Sep 30, 2021 | 810.00 Mn |
| Sep 30, 2021 | 810.00 Mn |
| Jun 30, 2021 | 900.10 Mn |
| Jun 30, 2021 | 900.10 Mn |
| Dec 31, 2020 | 950.10 Mn |
| Dec 31, 2020 | 950.10 Mn |
| Jun 28, 2020 | 11.40 Bn |
| Jun 28, 2020 | 11.40 Bn |
| Mar 31, 2020 | 33.10 Mn |
| Mar 31, 2020 | 33.10 Mn |